Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue (2013 - 2017)

Amphastar Pharmaceuticals' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $1.2 million for Q3 2017.

• In Q3 2017, Non-Current Deffered Revenue rose 623.21% year-over-year to $1.2 million; the TTM figure through Sep 2017 stood at $1.2 million (up 623.21% YoY), while the FY2016 annual figure was $97000.0, down 92.76% from the prior year.
• Non-Current Deffered Revenue was $1.2 million for Q3 2017 at Amphastar Pharmaceuticals, up from $423000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $2.6 million in Q4 2013 to a low of $97000.0 in Q4 2016.
• Historically, Non-Current Deffered Revenue has averaged $1.3 million across 5 years, with a median of $1.3 million in 2015.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deffered Revenue tumbled 92.76% in 2016, then soared 623.21% in 2017.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $2.6 million in 2013, then fell by 24.5% to $2.0 million in 2014, then sank by 32.44% to $1.3 million in 2015, then sank by 92.76% to $97000.0 in 2016, then jumped by 1152.58% to $1.2 million in 2017.
• The last three Non-Current Deffered Revenue figures came in at $1.2 million (Q3 2017), $423000.0 (Q2 2017), and $280000.0 (Q1 2017), per Business Quant data.